Our top pick for
Obalon Therapeutics, Inc is a medical devices business based in the US. Obalon Therapeutics shares (OBLN) are listed on the NASDAQ and all prices are listed in US Dollars. Obalon Therapeutics employs 2 staff and has a trailing 12-month revenue of around USD$2.3 million.
|Latest market close||USD$1.655|
|52-week range||USD$0.62 - USD$2.14|
|50-day moving average||USD$0.9097|
|200-day moving average||USD$0.8527|
|Wall St. target price||USD$0.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-13.267|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||13.36%|
|1 month (2020-12-17)||8.17%|
|3 months (2020-10-15)||93.34%|
|6 months (2020-07-15)||113.82%|
|1 year (2020-01-15)||-13.80%|
|2 years (2019-01-15)||-3.22%|
|3 years (2018-01-15)||N/A|
|5 years (2016-01-15)||N/A|
|Revenue TTM||USD$2.3 million|
|Gross profit TTM||USD$384,000|
|Return on assets TTM||-48.97%|
|Return on equity TTM||-122.54%|
|Market capitalisation||USD$10.3 million|
TTM: trailing 12 months
There are currently 355,994 Obalon Therapeutics shares held short by investors – that's known as Obalon Therapeutics's "short interest". This figure is 1.1% up from 352,189 last month.
There are a few different ways that this level of interest in shorting Obalon Therapeutics shares can be evaluated.
Obalon Therapeutics's "short interest ratio" (SIR) is the quantity of Obalon Therapeutics shares currently shorted divided by the average quantity of Obalon Therapeutics shares traded daily (recently around 87253.431372549). Obalon Therapeutics's SIR currently stands at 4.08. In other words for every 100,000 Obalon Therapeutics shares traded daily on the market, roughly 4080 shares are currently held short.
However Obalon Therapeutics's short interest can also be evaluated against the total number of Obalon Therapeutics shares, or, against the total number of tradable Obalon Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Obalon Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Obalon Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0557% of the tradable shares (for every 100,000 tradable Obalon Therapeutics shares, roughly 56 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Obalon Therapeutics.
Find out more about how you can short Obalon Therapeutics stock.
We're not expecting Obalon Therapeutics to pay a dividend over the next 12 months.
Obalon Therapeutics's shares were split on a 1:10 basis on 25 July 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Obalon Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Obalon Therapeutics shares which in turn could have impacted Obalon Therapeutics's share price.
Over the last 12 months, Obalon Therapeutics's shares have ranged in value from as little as $0.62 up to $2.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Obalon Therapeutics's is -0.9288. This would suggest that Obalon Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Obalon Therapeutics has bucked the trend.
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallow able capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. As of February 27, 2020, it had three company-managed retail treatment centers in California. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.